{"id":5502,"date":"2007-01-08T00:00:00","date_gmt":"2007-01-08T00:00:00","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-30T04:00:00","slug":"private-equity-finds-appetite-for-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.hedgeco.net\/news\/01\/2007\/private-equity-finds-appetite-for-pharmaceuticals.html","title":{"rendered":"Private equity finds appetite for pharmaceuticals"},"content":{"rendered":"<p>  <a href=\"http:\/\/feeds.feedburner.com\/~a\/reuters\/UKFundsNews?a=Z5uBRI\">LONDON (Reuters) &#8211; Private equity &#8212; traditionally wary of the complex drugs sector &#8212; is increasingly scanning the  pharmaceuticals industry for value, suggesting scope for sizeable buyouts in 2007.<\/a><\/p>\n<p>  Dutch-based Akzo Nobel (AKZO.AS: <a href=\"http:\/\/today.reuters.co.uk\/stocks\/Quote.aspx?symbol=AKZO.AS&amp;WTmodLoc=InvArt-C1-ArticlePage1\">Quote<\/a>, <a href=  \"http:\/\/today.reuters.co.uk\/stocks\/CompanyProfile.aspx?ticker=AKZO.AS&amp;WTmodLoc=InvArt-C1-ArticlePage1\">Profile<\/a> , <a href=  \"http:\/\/today.reuters.co.uk\/stocks\/ResearchReports.aspx?ticker=AKZO.AS&amp;WTmodLoc=InvArt-C1-ArticlePage1\">Research<\/a>) is talking to at least two buyout groups interested in its Organon  BioSciences division, while financial sponsors are among those likely to bid for Merck KGaA of Germany&#8217;s (MRCG.DE: <a href=  \"http:\/\/today.reuters.co.uk\/stocks\/Quote.aspx?symbol=MRCG.DE&amp;WTmodLoc=InvArt-C1-ArticlePage1\">Quote<\/a>, <a href=  \"http:\/\/today.reuters.co.uk\/stocks\/CompanyProfile.aspx?ticker=MRCG.DE&amp;WTmodLoc=InvArt-C1-ArticlePage1\">Profile<\/a> , <a href=  \"http:\/\/today.reuters.co.uk\/stocks\/ResearchReports.aspx?ticker=MRCG.DE&amp;WTmodLoc=InvArt-C1-ArticlePage1\">Research<\/a>) generic drugs unit, people familiar with the plans said this week.<\/p>\n<p><img decoding=\"async\" border=\"0\" src=\"http:\/\/feeds.feedburner.com\/~r\/reuters\/UKFundsNews\/~4\/71151217\"><br \/><strong><a href=\"http:\/\/feeds.feedburner.com\/~r\/reuters\/UKFundsNews\/~3\/71151217\/newsarticle.aspx\">Read Complete Article<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LONDON (Reuters) &#8211; Private equity &#8212; traditionally wary of the complex drugs sector &#8212; is increasingly scanning the pharmaceuticals industry for value, suggesting scope for sizeable buyouts in 2007. Dutch-based Akzo Nobel (AKZO.AS: Quote, Profile , Research) is talking to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-5502","post","type-post","status-publish","format-standard","hentry","category-syndicated"],"_links":{"self":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/5502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=5502"}],"version-history":[{"count":0,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/5502\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=5502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=5502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=5502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}